HomeCompareDNAY vs EPRT

DNAY vs EPRT: Dividend Comparison 2026

DNAY yields 153.85% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DNAY wins by $28.37M in total portfolio value
10 years
DNAY
DNAY
● Live price
153.85%
Share price
$1.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.43M
Annual income
$12,477,713.99
Full DNAY calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — DNAY vs EPRT

📍 DNAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNAYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNAY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNAY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNAY
Annual income on $10K today (after 15% tax)
$13,076.92/yr
After 10yr DRIP, annual income (after tax)
$10,606,056.89/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, DNAY beats the other by $10,595,142.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNAY + EPRT for your $10,000?

DNAY: 50%EPRT: 50%
100% EPRT50/50100% DNAY
Portfolio after 10yr
$14.25M
Annual income
$6,245,277.35/yr
Blended yield
43.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

DNAY
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-13.5
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNAY buys
0
EPRT buys
0
No recent congressional trades found for DNAY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNAYEPRT
Forward yield153.85%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$28.43M$63.4K
Annual income after 10y$12,477,713.99$12,840.73
Total dividends collected$26.36M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: DNAY vs EPRT ($10,000, DRIP)

YearDNAY PortfolioDNAY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$26,085$15,384.62$11,205$505.18+$14.9KDNAY
2$65,415$37,504.84$12,672$682.46+$52.7KDNAY
3$157,896$87,902.04$14,490$930.48+$143.4KDNAY
4$367,242$198,293.18$16,786$1,282.69+$350.5KDNAY
5$823,976$431,026.91$19,753$1,791.56+$804.2KDNAY
6$1,785,476$903,821.11$23,677$2,541.64+$1.76MDNAY
7$3,740,825$1,830,365.98$29,008$3,672.99+$3.71MDNAY
8$7,586,679$3,583,996.66$36,463$5,425.08+$7.55MDNAY
9$14,910,849$6,793,102.33$47,238$8,221.57+$14.86MDNAY
10$28,432,323$12,477,713.99$63,385$12,840.73+$28.37MDNAY

DNAY vs EPRT: Complete Analysis 2026

DNAYStock

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Full DNAY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this DNAY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNAY vs SCHDDNAY vs JEPIDNAY vs ODNAY vs KODNAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.